Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lifitegrast - Novartis

Next Previous
Drug Profile

Lifitegrast - Novartis

Alternative Names: Lifitegrast; OJL-332; SAR-1118; SAR-1119; SHP606; SPD606; Xiidra

Latest Information Update: 07 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sunesis Pharmaceuticals
  • Developer Novartis; SARcode Bioscience; Shire
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Benzofurans; Eye disorder therapies; Isoquinolines; Propionic acids; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • No development reported Allergic conjunctivitis; Atopic dermatitis; Diabetic macular oedema; Ocular inflammation; Psoriasis

Most Recent Events

  • 02 Feb 2024 Valeo Pharma and Novartis Pharmaceuticals amended the agreement for commercialisation of Lifitegrast
  • 29 Sep 2023 Bausch and Lomb acquires lifitegrast from Novartis
  • 24 Aug 2023 Bausch & Lomb announces expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 for lifitegrast
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top